GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » PB Ratio

Contineum Therapeutics (Contineum Therapeutics) PB Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-10), Contineum Therapeutics's share price is $17.92. Contineum Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $-2.80. Hence, Contineum Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Contineum Therapeutics's PB Ratio or its related term are showing as below:

CTNM's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.44
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Contineum Therapeutics PB Ratio Historical Data

The historical data trend for Contineum Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics PB Ratio Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
PB Ratio
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of Contineum Therapeutics's PB Ratio

For the Biotechnology subindustry, Contineum Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's PB Ratio falls into.



Contineum Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Contineum Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=17.92/-2.795
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Contineum Therapeutics  (NAS:CTNM) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Contineum Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus